The Value of Effective Lung Ventilation Area Ratio Based on CT Image Analysis Is a New Index to Predict the Shorter Outcome of Anti-melanoma Differentiation-Associated Protein 5 Positive Dermatomyositis Associated Interstitial Lung Disease: A Single-Center Retrospective Study

Changjian Wang1†, Jinfeng Du2†, Xilong Mei3†, Lingchao Guo1, Fangzhao Li1, Hong Luo4 and Fen Li2*†

1 College of Computer, National University of Defense Technology, Changsha, China, 2 Department of Rheumatology and Immunology, The Second Xiangya Hospital of Central South University, Changsha, China, 3 Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China, 4 Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, China

Background: Anti-melanoma differentiation-associated protein 5 (MDA5) positive dermatomyositis (MDA5+DM) patients have poor outcomes due to rapidly progressive interstitial lung disease (ILD). The accurate assessment of lung involvement is an urgent focus of research.

Methods: A computer-aided lung interstitial image analysis technology has been developed, and a quantitatively named effective lung ventilation area ratio (ELVAR) that calculates the proportion of the area outside the lung interstitium in lung tissue has been established. 55 newly diagnosed MDA5+DM patients and 46 healthy individuals, matched for age and gender, were enrolled in this study. MDA5+DM patients were classified into early death group or early survival group according to their survival state within 3 months after diagnosis. Clinical characteristics, laboratory and immunological test results, lung involvement (including ELVAR value) and treatment were compared between early death group and early survival group to determine an index that can predict prognoses of patients with MDA5+DM.

Results: There were significant differences between early death MDA5+DM patients and early survival MDA5+DM patients about 12 indices including age of onset, CRP, ferritin, albumin, and pulmonary involvement including severity of type I respiratory failure at diagnosis, P/F ratio, oxygen supplementation, values of ELVAR, FVC, and DLCO. The results of ROC analysis and correlation analysis showed the value of ELVAR had
INTRODUCTION

Idiopathic inflammatory myopathy (IIM) are heterogenous family of diseases (1). Dermatomyositis (DM) is a subtype of IIM that is characterized by skin rash and myopathy. The incidence of DM in the American population is approximately 1–6 per 100,000 people (2). Although the cause of DM is unknown, recent studies have revealed that anti-melanoma differentiation-associated protein 5 (MDA5) is associated with a subtype of DM (3). MDA5 promotes the production and activation of type I interferon (IFN), which is involved in the pathogenesis of DM (4, 5). Several clinical studies have found that MDA5+DM patients are more likely to develop rapidly progressive interstitial pneumonia (ILD) with life-threatening characteristics (6–9). Even after receiving active drug therapy, MDA5+DM patients may die soon after and 6-months mortality has been reported to be as high as 59% (10, 11). Therefore, the accurate assessment of prognoses of MDA5+DM patients is an urgent focus of research.

The advantage of high-resolution computed tomography (HRCT) is its ability to detect interstitial pneumonia with mild lesions in the early stage of the disease. The current limitation is the lack of a quantitative method to accurately identify subtle changes in abnormalities. Although several studies on the quantitative analysis of lung interstitial lesions in patients and mice have been conducted (12–16), results have not been convincing. Our study aimed to develop metric tools for clinicians to accurately assess the severity of interstitial pneumonia and establish a methodological plat that combines radiology and computer technology to predict prognoses of patients with MDA5+DM.

MATERIALS AND METHODS

Patient Data Collection

This single-center retrospective study was approved by the ethics committee of the Second Xiangya Hospital of Central South University (approval number: MDA5-IIM2020). All 55 MDA5+DM patients were newly onset and newly diagnosed fulfilling expert consensus from 239th ENMC International Workshop with MDA5 positive characteristic (17). Patients were hospitalized in the ward of Department of Rheumatology and Immunology between January 1st, 2015 and December 31st, 2018. Those who died within 3 months after diagnosis were classified into early death group, and those who had survived more than 3 months after diagnosis were classified into early survival group. Patient survival status was confirmed by medical records or by telephone. The survival status of patients in early survival group was verified 1 year later by telephone. Clinical characteristics, laboratory data, pulmonary involvement, antibody positive, and treatment information were obtained retrospectively from medical records. ILD diagnoses were verified by a radiologist and a respirologist (Figure 1). As control group, 46 healthy subjects, matched for age and gender, were included in the study to compare lung HRCT analysis results with the MDA5+DM patients. Our study complied with the Declaration of Helsinki and informed consents were obtained from all subjects (or their legally authorized representative in cases of patient death).

Computer-Aided Analysis of Lung HRCT

ILD include some basic radiology features in HRCT such as reticulations, sepal thickening, ground glass opacities, nodules, bronchiectasis and bronchiolectasis, honeycombing, consolidation, etc. All these features showed the differences of density (CT values) in images. Our quantitative analysis method was proposed from difference of CT values in Digital Imaging and Communications in Medicine (DICOM) of HRCT images. Simply, firstly, a special lung segmentation algorithm of interstitial lung disease was developed. Then, high-precision three-dimensional images of lung interstitium were reconstructed to detect interstitial pixels beyond the limit scope of naked eyes. An index named by Effective Lung Ventilation Area Ratio (ELVAR) were calculated inding pulmonary ventilation function.

Lung Segmentation

The process of lung segmentation was divided into four stages.

1. Lung coarse segmentation stage.
   
   Original lung HRCT images were collected from lung windows of every 1 mm scan (Figure 2A). Due to difference of CT value, the lung tissue can be separated with other human tissues from mediastinum to chest wall. This leaded to the generation of binary lung tissue region images (Figure 2B).

2. Lung contour detection stage.

good diagnostic value and widely correlation with many clinical characteristics. Univariate analysis and Multivariate analysis showed four factors including age of onset, ferritin, value of ELVAR, and oxygen supplementation >4 L/min significantly value for poor prognosis in MDA5+DM patients. A cutoff value of 0.835 about ELVAR had good predictive power for mortality within 3 months in 54.2% of MDA5+DM patients.

Conclusion: The value of ELVAR derived from computed tomography image analysis is a new index that can predict poor outcomes in MDA5+DM patients with rapidly progressive interstitial lung disease.

Keywords: dermatomyositis, anti-melanoma differentiation-associated protein 5 antibody, interstitial lung disease, prognosis, effective lung ventilation area ratio, computer-aided image analysis
The task of this stage was to draw the outlines of lung based on the coarse segmentation results. Firstly, a Gaussian function was adopted to eliminate noise, hence a transition zone was produced near the lung edge, so the binary lung tissue region images were filtered and smoothed (Figure 2C). Subsequently, a Laplace operator was used to produce the inner and outer boundaries on the lung edge. The outer boundary was selected as the candidate lung edge which included all irregular fragments near the boundaries (Figure 2D). The lung contour image was finally generated by filling the interior of the candidate lung edge (Figure 2E).

3. Lung hole elimination stage.

Because the lungs are near other organs, such as the heart, spleen, liver, and stomach, an obvious hole can appear in the CT images of the lower part of the lung. The goal of this stage was to detect and eliminate the hole area. Images detecting hole area (Figure 2D) were superimposed onto the lung contour images (Figure 2E) and were finally shown as Figure 2F. Using the region-growing method, the most lateral region of the lung was identified and set as the background, so that only the hole and blood vessels were preserved. Because blood vessels are small, the larger component with more than a specific number of pixels is regarded as the mask hole (Figure 2G). The quasi-images of lung with mask hole were obtained by subtracting the mask hole from the lung contour image(s).

4. Lung contour shrinkage stage.

The main objective of this stage was to generate a more accurate lung edge. First the candidate lung edges (Figure 2E or Figure 2H) were gradually contracted until they were coincided with the zero-crossing boundary, which were regarded as the accurate edges of the lung, therefore the images of lung masks were obtained (Figure 2I). An “and” operation on the original image (Figure 2A) and its lung mask (Figure 2I) would produce accurate lung segmentation result (Figure 2J). The total number of lung voxels (L) was obtained by counting the lung pixels from accurate lung segmentation results.

**Lung Interstitial Enhancement**

Because the lung interstitium was accompanied with blood vessels, and the pixels in the pipeline significantly differed in the direction of curvature, potential lung interstitial pixels not being detected by normally vision could be detected according to their curvature feature. This allowed the identification as many interstitial pixels as possible and the lung interstitial enhancement images were generated (Figure 2K). Finally, the total number of interstitium voxels (I) was obtained by counting the pixels of all the lung interstitial enhancement images.

**Calculation of Effective Lung Ventilation Area Ratio**

Using L, the total number of lung voxels, and I, the total number of interstitial voxels, ELVAR can show pulmonary ventilation function by applying the formula of \((L-I)/L\) (Figure 2L), which indirectly correlate with the scope of interstitial lung disease (Figure 3), i.e., low value of ELVAR means high scope of lung interstitium and low ventilation function. Using quantitative analysis method of lung segmentation and lung interstitial enhancement, the original lung HRCT images (Figures 4A1–A4,B1–B4) could be reconstructed into the lung interstitial enhancement images (Figures 4C1–C4,D1–D4) and high-precision three-dimensional images of the lung interstitium (Figures 4E1–E4), and the subtle lung interstitial changes
FIGURE 2 | Procedure of computer-aided analysis of lung HRCT. (A) Original lung HRCT images were collected; (B) Coarse binary lung tissue region images were acquired due to difference of CT value; (C) Binary lung tissue region images were filtered and smoothed by Gaussian function; (D) Outer boundary of binary lung tissue region images was selected by Laplace operator; (E) The interior of lung edge was filled in binary lung tissue region images; (F) Images detecting hole area were superimposed onto the lung contour images; (G) Images with mask hole were identified; (H) Quasi- images of lung with mask hole were obtained by subtracting the mask hole from the lung contour image; (I) Images of lung masks with accurate edge were obtained; (J) An “and” operation produced accurate lung segmentation images; (K) Lung interstitial enhancement images were generated according to curvature feature of lung interstitium; (L) ELVAR were calculated by formula of \((L-I) / L\), where \(L\) were the total number of lung voxels and \(I\) were the total number of interstitial voxels.

can be more easily observed by comparing the images from different patients.

Statistical Analysis
Statistical analysis was performed using the SPSS software version 26.0 (Chicago, IL, USA). Chi-square and Fisher’s exact tests were used to compare dichotomous data, and comparisons of continuous variables were performed using Student’s \(t\)-test or Wilcoxon’s rank-sum test. Correlation analysis between ELVAR and other variables were applied with Spearman or Kendall. The receiver operator curve (ROC) analysis was performed to evaluate the diagnostic performance of the statistical significance index. Cox proportional hazards regression analysis was used to assess the prognostic factors based on Duration from treatment to death or 1 year. Odds ratios (OR) were presented with 95% confidence intervals (CI). Twelve months of survival curves of different ELVAR values of MDA5+DM patients were drawn.
RESULTS
Comparisons Between Early Death Group and Early Survival Group
In Table 1, the data showed that duration from onset to treatment (months) between early death group and early survival group were 2.0(1.0,3.0) and 2.5(1.5,4.0). Therefore, we had enough evidence to show that our patients were at the early stage of disease. For the 55 MDA5+DM patients, there were no significant difference between two groups in duration from onset to treatment and treatment drugs, which indicted the time of diagnosis and different treatment were not the risk factors leading to different prognosis. There was a significant difference in age of onset between early death group and early survival group (56[47.25,61.75] vs. 50[44,55] years), which suggested that patients with elder age onset had a higher risk of early death. Obviously, the difference among duration from treatment to death or 1 year, mortality within 3 months, mortality within 12 months between above two groups were significant. Serum C reactive protein (CRP) and level of ferritin in early death group (12.29[5.81, 23.65] mg/L...
and 568.35[481.71, 583.02] ng/ml, respectively) were higher than those in early survival group (4.13[2.21,11.10] mg/L and 452.07[320.44, 561.12] ng/L). However, albumin levels in early death group were lower than those in early survival group (24.40[23.50, 27.35] vs. 30.30[27.60,34.10] g/L), which indicated that MDA5+/DM patients in early death group had aggressive systemic involvement. Other characteristics, such as the skin and muscle, laboratory data, myositis-specific autoantibody (MSA), myositis associated autoantibody (MAA) revealed no significant differences between groups (Table 1).

For pulmonary involvement, there were no significant differences in cough, pneumothorax, ILD diagnosis, or radiological features of ILD. The values of ELVAR indirectly reflecting the severity of interstitial structure were significantly different between early death group and early survival group (0.7973[0.7458, 0.8338] vs. 0.8685[0.8155, 0.8956], Figure 5B). The differences among severity of type I respiratory failure at diagnosis (no, mild and severe), P/F ratio and oxygen supplementation (0 and >4 L/min) between two groups were significantly. The two indices of the lung function test, FVC % predicted (FVC PRED) and DLCO% predicted (DLCO%PRED), were 42 (37, 53) and 35 (28, 46)%, respectively, in early death group, which were lower than those in early survival group (79 [78, 81] and 79 [78, 80]%).

ROC Analysis and Correlation Analysis

The ROC analysis of the eight significantly different indices (i.e., age at onset, CRP, level of ferritin, value of ELVAR, P/F ratio, level of albumin, FVC and DLCO) showed that value of ELVAR, level of albumin and P/F ratio had well diagnostic value for early death within 3 months with higher sensitivity (71.8, 87.2, and 87.2%) and specificity (81.2, 75.0, and 75.0%). FVC and DLCO with lower specificity will be verified with more data in the future because only two patients underwent a lung function test and the remaining 14 patients did not accept the lung function test because of intolerability or early death in the early death group of the study (Table 2). As for correlation analysis, level of albumin, value of ELVAR and P/F ratio had different correlation with all indices except for FVC and DLCO, the scope of correlation about value of ELVAR lied in moderate range (Table 3). ROC analysis and correlation analysis indicted value of ELVAR had good diagnostic and correlation with clinical characteristics.

Clinical Significance of ELVAR Values

Distribution and Comparison of ELVAR Values Between Healthy Controls and MDA5+/DM Patients

Using computer-assisted lung HRCT image analysis, we found that the lungs of MDA5+DM patients differed significantly from those of healthy controls. There were interstitial hyperplasia structures in the outer lung area of patients. In severe cases, it had spread to the middle and upper regions of the lung (Figure 4). Results showed that value of ELVAR in healthy controls were higher than those in MDA5+/DM patients (0.9351[0.9311, 0.9414] vs. 0.8487[0.8018, 0.8875]; Figure 5A).

Difference Between the Lower ELVAR Group and Higher ELVAR Group

The ROC analysis of ELVAR values showed that the best diagnostic cutoff value was 0.835 (Figure 5C). Based on this ELVAR cutoff value, 24 MDA5+/DM patients were classified into the lower ELVAR group (ELVAR < 0.835) and 31 into the
### TABLE 1 | Comparison between early death group and early survival group in MDA5+DM.

| Variables | Early death group N = 16 | Early survival group N = 39 | P-value |
|-----------|-------------------------|----------------------------|---------|
| Female, n (%) | 14(87.5) | 28(71.8) | 0.217 |
| Age of onset (y) | 56(47.25, 61.75) | 50(44, 55) | 0.033* |
| Duration from onset to treatment, m | 2.0(1.0, 3.0) | 2.5(1.5, 4.0) | 0.315 |
| Duration from treatment to death or 1 year, m | 0.75(0.5, 1.5) | 12(12.0, 12.0) | 0.000* |
| Mortality within 3 months, n (%) | 16(100) | 0 (0) | 0.000* |
| Mortality within 12 months, n (%) | 16(100) | 1(2.6) | 0.000* |
| Smoking history, n (%) | 4(25.0) | 4(10.3) | 0.163 |

**Clinical feature**

| | Early death group | Early survival group | P-value |
|----------------|----------------|---------------------|---------|
| Muscle weakness, n (%) | 8(50.0) | 25(64.1) | 0.337 |
| Gottron sign, n (%) | 5(31.3) | 9(23.1) | 0.531 |
| Heliotrop rash, n (%) | 4(25.0) | 15(38.5) | 0.345 |
| Skin ulcer, n (%) | 2(12.5) | 12(30.8) | 0.162 |
| Raynaud phenomenon, n (%) | 0(0.0) | 3(7.7) | 0.258 |
| Fever, n (%) | 7(43.8) | 8(20.5) | 0.082 |
| Cough, n (%) | 2(12.5) | 9(23.1) | 0.377 |
| Dyspnea, n (%) | 12(75.0) | 22(56.4) | 0.202 |
| Pneumothorax, n (%) | 1(6.3) | 1(2.6) | 0.511 |
| Concomitant neoplasia, n (%) | 0(0.0) | 1(2.6) | 0.522 |

**Laboratory data**

| | Early death group | Early survival group | P-value |
|----------------|----------------|---------------------|---------|
| Neutrophil Count, X10$^9$/L | 3.31(2.57, 4.59) | 3.29(2.43, 4.86) | 0.978 |
| Lymphocyte Count, X10$^9$/L | 0.86(0.45, 1.14) | 0.85(0.56, 1.21) | 0.670 |
| ESR, mm/hr | 43(25, 61) | 38.5(28.5, 56.25) | 1.000 |
| CRP, mg/L | 12.29(6.1, 23.65) | 4.13(2.11, 11.10) | 0.026* |
| CK, IU/L | 80.10(49.30, 144.23) | 84.70(41.50, 191.40) | 0.704 |
| LDH, IU/L | 382.55(351.30, 535.40) | 364.30(266.90, 445.40) | 0.069 |
| Myoglobin, ug/L | 101(57.65, 111.35) | 66.20(38.50, 95.20) | 0.132 |
| Albumin, g/L | 24.40(23.50, 27.35) | 30.30(27.60, 34.10) | 0.000* |
| Ferritin, ng/ml | 568.35(481.71, 583.02) | 452.07(320.44, 561.12) | 0.001* |
| PCT, ng/ml | 0.11(0.053, 0.193) | 0.07(0.04, 0.105) | 0.089 |

**Pulmonary involvement**

| | Early death group | Early survival group | P-value |
|----------------|----------------|---------------------|---------|
| ILD diagnosis, n (%)$^a$ | 16(100) | 32(82.1) | 0.072 |
| Feature of ILD at diagnosis | | | |
| Reticulations, n (%) | 3(18.75) | 11(28.21) | 0.469 |
| Septal thickening, n (%) | 8(50.00) | 11(28.21) | 0.126 |
| Ground glass opacities, n (%) | 4(25.00) | 9(23.08) | 0.880 |
| Nodules, n (%) | 5(31.25) | 7(17.95) | 0.282 |
| Bronchiectasis/Bronchiolectasis, n (%) | 1(6.25) | 2(5.13) | 0.869 |
| Honeycombing, n (%) | 1(6.25) | 1(2.56) | 0.511 |
| Consolidation, n (%) | 12(75.00) | 22(56.41) | 0.202 |
| ELVAR | 0.7973(0.7458, 0.8338) | 0.8685(0.8155, 0.8956) | 0.001* |
| Severity of type I respiratory failure | | | |
| no/mild/moderate/severe, n (%)$^b$ | 4/3/7/2 (25.0/18.8/43.7/12.5) | 31/5/3/0 (79.5/12.8/7.7/0.0) | 0.000* |
| no, n (%) | 4(25.0) | 31(79.5) | 0.000* |
| mild, n (%) | 3(18.8) | 5(12.8) | 0.575 |
| moderate, n (%) | 7(43.7) | 3(7.7) | 0.002* |
| severe, n (%) | 2(12.5) | 0(0) | 0.026* |
| P/F ratio, mmHg | 226(188, 297.75) | 417(312, 476) | 0.000* |
| Oxygen supplementation | | | |
| O2/1-2/3-4/>-4, L/min, n (%) | 3/1/6/6 (18.8/8.2/37.5/37.5) | 19/8/9/3 (48.7/20.5/23.1/7.7) | 0.003* |

(Continued)
TABLE 1 | Continued

| Variables | MDA5+DM patients |  |
|-----------|------------------|---|
| Early death group N = 16 | Early survival group N = 39 | P-value |
| OL/min, n (%) | 3(18.8) | 19(48.7) | 0.040* |
| 1–2L/min, n (%) | 1(6.2) | 8(20.5) | 0.198 |
| 3–4L/min, n (%) | 6(37.5) | 9(23.1) | 0.280 |
| >4L/min, n (%) | 6(37.5) | 3(7.7) | 0.007* |
| FVC, % PRED | 42(37, 53) | 9(78, 81) | 0.004* |
| DLCO, % PRED | 35(25, 46) | 79(78, 80) | 0.004* |
| Antibody positive | | | |
| ANA, n (%) | 2(12.5) | 15(38.5) | 0.061 |
| MAA profile | | | |
| SSA, n (%) | 0(0.0) | 8(20.5) | 0.052 |
| SSB, n (%) | 0(0.0) | 3(7.7) | 0.258 |
| Ro-52, n (%) | 14(87.5) | 25(64.1) | 0.086 |
| CENP-B, n (%) | 1(6.3) | 1(2.6) | 0.511 |
| Ku, n (%) | 0(0.0) | 1(2.6) | 0.522 |
| PM-Scl, n (%) | 0(0.0) | 2(5.1) | 0.361 |
| MSA profile, n (%) | 5(31.3) | 8(20.5) | 0.399 |
| anti-ARS antibodies, n (%) | 1(6.3) | 4(10.3) | 0.642 |
| Jo-1, n (%) | 0(0.0) | 2(5.1) | 0.361 |
| PL-7, n (%) | 0(0.0) | 1(2.6) | 0.522 |
| PL-12, n (%) | 0(0.0) | 2(5.1) | 0.361 |
| EJ, n (%) | 0(0.0) | 0(0.0) | 1.000 |
| OJ, n (%) | 1(6.3) | 0(0.0) | 0.118 |
| Non anti ARS antibodies, n (%) | 4(25.0) | 6(15.4) | 0.405 |
| SRP, n (%) | 0(0.0) | 2(5.1) | 0.361 |
| TIF1-γ, n (%) | 1(6.3) | 2(5.1) | 0.869 |
| Mi-2ik, n (%) | 3(18.8) | 2(5.1) | 0.114 |
| SAE, n (%) | 0(0.0) | 1(2.6) | 0.522 |
| Treatment | | | |
| Glucocorticoid, <1 /≥1 mg/kg/d, n (%) | 6(10/37,5/62,5) | 22/17(56.4, 43.6) | 0.207 |
| Methotrexate, n (%) | 0(0.0) | 5(12.8) | 0.137 |
| Cyclophosphamide, n (%) | 12(75.0) | 27(69.2) | 0.672 |
| Cyclosporine A, n (%) | 1(6.3) | 7(17.9) | 0.268 |
| Tacrolimus, n (%) | 1(6.3) | 6(15.4) | 0.360 |
| Plasma exchange, n (%) | 4(25.0) | 3(7.7) | 0.083 |
| Single drug or Combination drugs | | | |
| 1 drug | 2(12.5) | 6(15.4) | 0.785 |
| 2 drugs | 11(68.8) | 20(51.3) | 0.240 |
| 3 drugs | 2(12.5) | 11(28.2) | 0.217 |
| ≥4 drugs | 1(6.3) | 2(5.1) | 0.869 |

*P < 0.05.

**ILD diagnosis by a radiologist and a respirologist simultaneous.

ANA, antinuclear antibody; CRP, C reactive protein; CK, creatine kinase; DLCO, carbon monoxide diffusing capacity; ELVAR, Efficient Lung Ventilation Area Ratio; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; ILD, interstitial lung disease; LDH, Lactic dehydrogenase; MDA5, melanoma differentiation associated gene 5; PCT, procalcitonin; P/F ratio, PaO2/FiO2 ratio; SAE, anti-small ubiquitin-like modifier antibody; SRP, signal recognition particle; TIF1-γ, transcription intermediary factor 1-gamma.

higher ELVAR group (ELVAR ≥ 0.835). The comparison revealed that the rates of mortality within 3 months in the lower and higher ELVAR groups were 54.2 vs. 9.7%, respectively, whereas 12-month mortality rates were 54.2 vs. 12.9%, respectively (Figure 5D), which indicated that the ELVAR value was more predictive of early mortality within 3 months. The differences among severity of type I respiratory failure at diagnosis (no), P/F ratio and oxygen supplementation (0 and >4 L/min) between two groups were significantly. For the other indices, dyspnea in lower ELVAR group was more frequent than that in higher ELVAR group (79.2 vs. 48.4%), and lymphocyte count of lower ELVAR group was lower than that of higher
ELVAR as a Risk Factor for Poor Prognosis of MDA5+DM Patients

To identify the indicators of poor outcomes in MDA5+DM patients, we performed Cox regression analysis. Results of the univariate analysis revealed that age of onset, CRP, myoglobin, albumin, ferritin, PCT, ELVAR, severity of type I respiratory failure, P/F ratio, oxygen supplementation, FVC and DLCO were significantly associated with poor outcomes. Only four factors including age of onset, ferritin, value of ELVAR and oxygen supplementation >4 L/min showed significantly value for poor prognosis in MDA5+DM patients in the multivariate analysis (Table 5). FVC and DLCO were excluded from the multivariate analysis.
TABLE 2 | Analysis of ROC by eight significantly different indices between early death group and early survival group.

| Analysis of ROC | AUC | Value of cut-off | Sensitivity (%) (C.I.) | Specificity (%) (C.I.) | p value |
|----------------|-----|-----------------|------------------------|------------------------|---------|
| Age at onset   | 0.684 | 54.5           | 56.3                  | 74.4                  | 0.033*  |
| CRP            | 0.692 | 8.51           | 68.8                  | 74.4                  | 0.026*  |
| Ferritin       | 0.776 | 588.34         | 53.8                  | 96.9                  | 0.004*  |
| ELVAR          | 0.795 | 0.835          | 71.8                  | 81.2                  | 0.001*  |
| P/F ratio      | 0.822 | 289.5          | 87.2                  | 75.0                  | 0.000*  |
| Albumin        | 0.829 | 26.65          | 100.0                 | 0.0                   | 0.004*  |
| FVC*           | 1.000 | 64.5           | 100.0                 | 0.0                   | 0.004*  |
| DLCO*          | 1.000 | 61.0           | 100.0                 | 0.0                   | 0.004*  |

* P < 0.05.

* Only two patients in early death group accepted lung function test and other 14 patients in early death group didn’t accept lung function test for rapidly death or intolerable. CRP, C reactive protein; DLCO, carbon monoxide diffusing capacity; ELVAR, Efficient Lung Ventilation Area Ratio; FVC, forced vital capacity; P/F ratio, PaO2/FiO2 ratio.

because of insufficient data due to patient intolerability and early-death patients.

**DISCUSSION**

It is widely known that the short-term prognosis of MDA5+DM-ILD patients is poor (18). Accurate prediction of MDA5+DM patient outcomes is a key issue in clinical practice. In this study, we established a computer-aided lung interstitial image analysis approach. ELVAR was obtained by calculating the proportion of areas outside the lung interstitium in lung tissue that can indirectly evaluates the severity of lung interstitial lesions. Our results showed that ELVAR values in MDA5+DM patients who died within 3 months after diagnosis were significantly reduced than those who were survival after 3 months. ROC analysis and correlation analysis about value of ELVAR showed that ELVAR values have good predictive power for 3-month mortality and widely correlation with many clinical indices, which indicates that it may be a powerful tool for clinicians to evaluate poor outcomes in MDA5+DM-ILD.

Recently a variety of lung segmentation methods have been advanced (19). According to the different segmentation features used, lung segmentation methods can be divided into threshold-based methods (20), region-based methods (21), and shape-based methods (22). However, these methods had different degrees of partial lung tissue loss. A recent study used deep learning and feature learning to obtain better segmentation results by training with large samples (23). Software package named “CT Pneumonia Analysis” applying in the similar mechanism was used in study by S Ye recently (24). Our design idea was to extent different. We considered deep learning above cannot guarantee the accuracy results for inconsistent diagnosis of complex images and was not feasible for rare diseases such as MDA5+DM. We proposed another lung tissue segmentation method that was suitable for CT images of interstitial lung disease. The lung
**TABLE 4 |** Comparison between lower ELVAR group and higher ELVAR group.

| Variables | MDA5 + DM patients | lower ELVAR group N = 24 | higher ELVAR group N = 31 | P-value |
|-----------|--------------------|--------------------------|---------------------------|---------|
| Female, n (%) | | 20(83.3) | 22(71.0) | 0.289 |
| Age of onset (y) | | 53(46.25, 59.25) | 52(42, 59) | 0.440 |
| Duration from onset to treatment, m | | 3.0(2.0, 4.0) | 2.0(1.0, 3.0) | 0.095 |
| Duration from treatment to death or 1 year, m | | 2.25(0.5, 12.0) | 12.0(12.0, 12.0) | 0.000* |
| Mortality within 3 months, n (%) | | 13(54.2) | 30(7) | 0.000* |
| Mortality within 12 months, n (%) | | 13(54.2) | 4(12.9) | 0.001* |
| Smoking history, n (%) | | 3(12.5) | 5(16.1) | 0.708 |

**Clinical feature**

| Muscle weakness, n (%) | | 12(50.0) | 21(67.7) | 0.187 |
| Gottron sign, n (%) | | 7(29.2) | 7(22.8) | 0.582 |
| Heliotrop rash, n (%) | | 8(33.3) | 11(35.5) | 0.869 |
| Skin ulcer, n (%) | | 6(25.0) | 8(25.8) | 0.946 |
| Raynaud phenomenon, n (%) | | 0(0) | 39(7) | 0.120 |
| Fever, n (%) | | 8(33.3) | 7(22.6) | 0.379 |
| Cough, n (%) | | 4(16.7) | 7(22.6) | 0.590 |
| Dyspnea, n (%) | | 19(79.2) | 15(48.4) | 0.021* |
| Pneumothorax, n (%) | | 1(4.1) | 1(3.2) | 0.855 |
| Concomitant neoplasia, n (%) | | 0(0) | 1(2.6) | 0.379 |

**Laboratory data**

| Neutrophil Count, X10\(^9\)/L | | 3.31(2.67, 4.74) | 3.29(2.37, 4.63) | 0.754 |
| Lymphocyte Count, X10\(^9\)/L | | 0.65(0.50, 0.87) | 0.92(0.63, 1.34) | 0.022* |
| ESR, mm/hr | | 43(31, 62) | 32.50(24.50, 56.25) | 0.164 |
| CRP, mg/L | | 21(2.60, 18.03) | 5.16(2.60, 11.10) | 0.222 |
| CRP, mg/L | | 76.20(45.83, 144.23) | 87.40(44.8, 201.2) | 0.905 |
| LDH, IU/L | | 378.80(332.80, 525.55) | 358.50(268.25, 441.06) | 0.157 |
| Myoglobin, ug/L | | 69.60(49.50, 108.78) | 69.40(38.5, 95.2) | 0.457 |
| Albumin, g/L | | 27.40(24.33, 30.83) | 29.80(26.7, 34.2) | 0.051 |
| Ferritin, ng/ml | | 519.05(375.45, 570.19) | 485.18(357.90, 562.67) | 0.131 |
| PCT, ng/ml | | 0.09(0.053, 0.14) | 0.07(0.035, 0.11) | 0.214 |

**Pulmonary involvement**

| ILD diagnosis, n (%) | | 22(91.7) | 26(83.9) | 0.394 |

**Radiological feature of ILD at diagnosis**

| Reticulations, n (%) | | 6(25.0) | 8(25.8) | 0.946 |
| Septal thickening, n (%) | | 8(33.3) | 11(35.5) | 0.869 |
| Ground glass opacities, n (%) | | 7(29.2) | 6(19.4) | 0.400 |
| Nodules, n (%) | | 3(12.5) | 9(29.0) | 0.145 |
| Bronchiectasis/Bronchiolectasis, n (%) | | 1(4.2) | 2(6.5) | 0.714 |
| Honeycombing, n (%) | | 1(0.0) | 2(6.5) | 0.209 |
| Consolidation, n (%) | | 18(75.0) | 16(51.6) | 0.079 |

**ELVAR**

| 0.7893(0.7442, 0.8143) | 0.8823(0.8638, 0.9025) | 0.000* |

**Severity of type I respiratory failure**

| no/mild/moderate/severe, n (%) | | 11/4/7/2 (45.8/16.7/29.2/8.3) | 24/4/3/0 (77.4/12.9/9.7/0) | 0.009* |
| no, n (%) | | 11(46.8) | 24(77.4) | 0.017* |
| mild, n (%) | | 4(16.7) | 4(12.9) | 0.697 |
| moderate, n (%) | | 7(29.2) | 3(9.7) | 0.066 |
| severe, n (%) | | 2(8.3) | 0(0) | 0.105 |
| P/F ratio, mmHg | | 26(192.5, 419) | 417(303, 471) | 0.025* |
edges produced by our method were more accurate than those of above mentioned traditional methods (25). The outstanding feature lying in our computer-aided analysis of lung HRCT were outer boundary of binary lung tissue region images selected by Laplace operator and interstitial enhancement generated according to curvature feature of lung interstitium. Because our imagine analysis had based on high density structure from HRCT, we can apprehension that imagine of normal lung interstitium and abnormal imagine including consolidation, reticulations, septal thickening, ground glass opacities, nodules, bronchiectasis,

### TABLE 4 | Continued

| Variables | MDA5+ DM patients |
|-----------|-------------------|
|           | lower ELVAR group N = 24 | higher ELVAR group N = 31 | P-value |
| Oxygen supplementation 0/1–2/3–4/ &gt; 4L/min, n (%) | 5/5/7/7 (20.8/20.8/29.2/29.2) | 17/4/8/2 (54.8/12.9/25.8/6.5) | 0.007* |
| 0L/min, n (%) | 5 (20.8) | 17 (54.8) | 0.011* |
| 1–2L/min, n (%) | 5 (20.8) | 4 (12.9) | 0.435 |
| 3–4L/min, n (%) | 7 (29.2) | 8 (25.8) | 0.783 |
| &gt; 4L/min, n (%) | 7 (29.2) | 2 (6.5) | 0.025* |
| FVC, % PRED | 79 (71.82) | 79 (78.81) | 0.843 |
| DLCO, % PRED | 79 (77.25–79.75) | 79 (56.50–80.25) | 0.902 |
| Antibody positive | | | |
| ANA, n (%) | 7 (29.2) | 10 (32.3) | 0.807 |
| MAA profile | 19 (79.2) | 22 (71.0) | 0.493 |
| SSA, n (%) | 2 (8.3) | 6 (19.4) | 0.255 |
| SSB, n (%) | 2 (8.3) | 1 (3.2) | 0.412 |
| Ro-52, n (%) | 18 (75.0) | 21 (67.7) | 0.560 |
| CENP-B, n (%) | 1 (4.2) | 1 (3.2) | 0.855 |
| Ku, n (%) | 0 (0.0) | 1 (3.2) | 0.379 |
| PM-Scl, n (%) | 2 (8.3) | 0 (0.0) | 0.105 |
| MSA profile, n (%) | 7 (29.2) | 6 (19.4) | 0.400 |
| anti-ARS antibodies, n (%) | 2 (8.3) | 3 (9.7) | 0.865 |
| Jo-1, n (%) | 0 (0.0) | 2 (6.5) | 0.209 |
| PL-7, n (%) | 0 (0.0) | 1 (3.2) | 0.379 |
| PL-12, n (%) | 1 (4.2) | 1 (3.2) | 0.855 |
| EJ, n (%) | 0 (0.0) | 0 (0.0) | 1.000 |
| OJ, n (%) | 1 (4.2) | 0 (0.0) | 0.256 |
| Non-anti-ARS antibodies, n (%) | 5 (20.8) | 5 (16.1) | 0.657 |
| SRP, n (%) | 1 (4.2) | 1 (3.2) | 0.855 |
| TIF1-γ, n (%) | 1 (4.2) | 2 (6.5) | 0.714 |
| Mi-2γ, n (%) | 2 (8.3) | 3 (9.7) | 0.865 |
| SAE, n (%) | 1 (4.2) | 0 (0.0) | 0.256 |
| Treatment | | | |
| Glucocorticoid, &lt; 1 / &gt; 1 mg/kg/d, n (%) | 12/12 (50.0/50.0) | 16/15 (51.6/48.4) | 0.906 |
| Methotrexate, n (%) | 2 (8.3) | 3 (9.7) | 0.865 |
| Cyclophosphamide, n (%) | 19 (79.2) | 20 (64.5) | 0.240 |
| Cyclosporine A, n (%) | 1 (4.2) | 7 (22.6) | 0.057 |
| Tacrolimus, n (%) | 2 (8.3) | 5 (16.1) | 0.394 |
| Plasma exchange, n (%) | 4 (16.7) | 3 (9.7) | 0.445 |
| Single drug or Combination drugs | | | |
| 1 drug | 3 (12.5) | 5 (16.1) | 0.706 |
| 2 drugs | 15 (62.5) | 16 (51.6) | 0.424 |
| 3 drugs | 5 (20.8) | 8 (25.8) | 0.670 |
| ≥ 4 drugs | 1 (4.2) | 2 (6.5) | 0.714 |

*P &lt; 0.05.

**ILD diagnosis by a radiologist and a respirologist simultaneously.

ANA, antinuclear antibody; CRP, C reactive protein; CK, creatine kinase; DLCO, carbon monoxide diffusing capacity; ELVAR, Efficient Lung Ventilation Area Ratio; ESR, erythrocyte sedimentation rate; FVC, forced vital capacity; ILD, interstitial lung disease; LDH, Lactic dehydrogenase; MDA5, melanoma melanoma differentiation-associated gene-5; PCT, procalcitonin; P/F ratio, PaO2/FiO2 ratio; SAE, anti-small ubiquitin-like modifier antibody; SRP, signal recognition particle; TIF1-γ, transcription intermediary factor 1-gamma.
| Variable                          | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR (95%CI)          | P-value               | HR (95%CI)          | P-value               |
| Female                           | 0.420(0.095–1.852)  | 0.252                 | 9.842(1.434–67.528) | 0.020*                |
| Age at onset                     | 2.776(1.031–7.471)  | 0.043*                |                       |                       |
| Duration from onset to treatment | 0.550(0.200–1.515)  | 0.247                 |                       |                       |
| Mortality within 3 months        | 0.000(0.000–1.845)  | 0.069                 |                       |                       |
| Mortality within 12 months       | 0.001(0.000–1.294)  | 0.059                 |                       |                       |
| Smoking history                  | 2.309(0.743–7.171)  | 0.148                 |                       |                       |
| Muscle weakness                  | 0.616(0.231–1.644)  | 0.334                 |                       |                       |
| Gottron sign                     | 1.311(0.455–3.776)  | 0.616                 |                       |                       |
| Heliotrop rash                   | 0.598(0.193–1.856)  | 0.374                 |                       |                       |
| Skin ulcer                       | 0.384(0.087–1.689)  | 0.205                 |                       |                       |
| Raynaud phenomenon               | 0.045(0.000–351.921)| 0.498                 |                       |                       |
| Fever                            | 2.336(0.869–6.282)  | 0.093                 |                       |                       |
| Cough                            | 0.527(0.120–2.321)  | 0.397                 |                       |                       |
| Dyspnea                          | 2.254(0.725–7.002)  | 0.160                 |                       |                       |
| Pneumothorax                     | 2.142(0.282–16.282) | 0.462                 |                       |                       |
| Concomitant neoplasia            | 0.048(0.000–21618.008)| 0.698                |                       |                       |
| Neutrophil Count                 | 0.272(0.036–2.058)  | 0.207                 |                       |                       |
| Lymphocyte Count                 | 0.448(0.163–1.237)  | 0.121                 |                       |                       |
| ESR                              | 0.328(0.093–1.156)  | 0.083                 |                       |                       |
| CRP                              | 4.665(1.615–13.474) | 0.004*                | 2.172(0.480–9.841)   | 0.314                 |
| CK                               | 5.104(0.674–38.674) | 0.115                 |                       |                       |
| LDH                              | 36.822(0.430–3154.017) | 0.112               |                       |                       |
| Myoglobin                        | 3.004(1.124–8.031)  | 0.028*                | 3.347(0.783–14.306)  | 0.103                 |
| Albumin                          | 0.109(0.035–0.342)  | 0.000*                | 0.307(0.053–1.785)   | 0.189                 |
| Ferritin                         | 7.897(2.862–21.793) | 0.000*                | 11.255(2.862–46.786) | 0.005*                |
| PCT                              | 2.793(1.012–7.707)  | 0.047*                | 0.954(0.217–4.187)   | 0.950                 |
| ILD diagnosis                    | 25.672(0.061–10818.508)| 0.293              |                       |                       |
| Reticulations                    | 0.630(0.179–2.210)  | 0.470                 |                       |                       |
| Septal thickening                | 2.228(0.835–5.940)  | 0.109                 |                       |                       |
| Ground glass opacities           | 1.202(0.388–3.730)  | 0.750                 |                       |                       |
| Nodules                          | 1.542(0.535–4.440)  | 0.422                 |                       |                       |
| Bronchiectasis/Bronchiolectasis  | 1.413(0.186–10.712) | 0.738                 |                       |                       |
| Honeycombing                     | 2.142(0.282–16.282) | 0.462                 |                       |                       |
| Consolidation                    | 2.081(0.671–6.454)  | 0.205                 |                       |                       |
| ELVAR                            | 0.133(0.038–0.468)  | 0.002*                | 0.098(0.017–0.564)   | 0.009*                |
| Severity of type I respiratory failure | 7.399(2.370–23.106)       | 0.001*               | 0.001(0.000–4.093E+100) | 0.996               |
| Mild                             | 8.453(3.075–23.234) | 0.000*                | 5.369(0.676–42.654)  | 0.112                 |
| Severe                           | 8.516(1.719–42.197) | 0.009*                | 1.062(0.088–12.815)  | 0.962                 |
| P/F ratio                        | 0.095(0.030–0.298)  | 0.000*                | 0.000(0.000–4.865E+99)| 0.941                 |
| Oxygen supplementation           |                     |                       |                       |                       |
| 1–2                              | 3.370(0.958–11.853) | 0.058                 |                       |                       |
| 3–4                              | 4.802(1.542–14.964) | 0.007*                | 3.476(0.286–42.194)  | 0.328                 |
| >4                               | 3.711(1.337–10.299) | 0.012*                | 0.010(0.001–0.146)   | 0.001*                |
| FVC                              | 1.000               | 1.000                 |                       |                       |
| DLCO                             | 1.000               | 1.000                 |                       |                       |
| ANA                              | 0.296(0.067–1.303)  | 0.107                 |                       |                       |
| SSA                              | 0.037(0.000–11.180) | 0.259                 |                       |                       |
| SSB                              | 0.045(0.000–351.921)| 0.498                 |                       |                       |
| RQ-52                            | 2.985(0.677–13.150) | 0.148                 |                       |                       |
### TABLE 5 | Continued

| Variable                  | Univariate analysis | Multivariate analysis |
|---------------------------|---------------------|-----------------------|
|                           | HR (95%CI)          | P- value              | HR (95%CI)          | P- value |
| CENP-B                    | 2.142(0.282–16.282) | 0.462                 |                     |          |
| Ku                        | 0.048(0.000–216181.008) | 0.698               |                     |          |
| PM-Scl                    | 0.047(0.000–2532.428) | 0.582                 |                     |          |
| Jo-1                      | 0.047(0.000–2532.428) | 0.582                 |                     |          |
| PL-7                      | 0.048(0.000–216181.008) | 0.698               |                     |          |
| PL-12                     | 0.047(0.000–2532.428) | 0.582                 |                     |          |
| OJ                        | 4.085(0.531–31.432)  | 0.176                 |                     |          |
| SRP                       | 0.047(0.000–216181.008) | 0.698               |                     |          |
| TIF1-γ                    | 1.239(0.164–9.388)  | 0.836                 |                     |          |
| Mi-2p                     | 2.196(0.625–7.713)  | 0.220                 |                     |          |
| SAE                       | 0.048(0.000–216181.008) | 0.698               |                     |          |
| Glucocorticoid            | 1.831(0.665–5.043)  | 0.242                 |                     |          |
| Methotrexate              | 0.042(0.000–48.056)  | 0.378                 |                     |          |
| Cyclophosphamide          | 1.176(0.379–3.648)  | 0.779                 |                     |          |
| Cyclosporine A            | 0.363(0.048–2.747)  | 0.326                 |                     |          |
| Tacrolimus                | 0.415(0.055–3.143)  | 0.395                 |                     |          |
| Plasma exchange           | 2.812(0.900–8.787)  | 0.075                 |                     |          |
| Single drug or Combination drugs |                     |                      |                     |          |
| 1 drug                    | 0.894(0.203–3.935)  | 0.882                 |                     |          |
| 2 drugs                   | 1.119(0.254–4.923)  | 0.882                 |                     |          |
| 3 drugs                   | 0.514(0.146–1.804)  | 0.299                 |                     |          |
| ≥4 drugs                  | 239(0.164–9.388)    | 0.836                 |                     |          |

*P < 0.05.

NC, only 2 patients in early death group accepted lung function test and other 14 patients in early death group didn’t accept lung function test for rapidly death or intolerable. Hence multivariate analysis didn’t include the FVC and DLCO into analysis.

honey combing, cysts could be detected and analysis (26). Because ELVAR was defined with the formula of (L—I)/L (L was the total number of lung voxels and I was the total number of interstitial voxels), which could easily be understood that the level of ELVAR was negative correlation with the scope of abnormal lung interstitium, i.e., high value of ELVAR meant less scope of interstitium and high ventilation, however, the lower value of ELVAR referred to large scope of interstitium and low ventilation which possibly indicated poor disease outcome. Finally in our single-center retrospective study, we calculated that value of ELVAR in healthy controls was 0.938 while cut off value of ELVAR by ROC analysis in MDA5+DM-ILD was 0.835. Patients with low ELVAR values (< 0.835) had a 54.2% chance of dying within 3 months, which may be valuable for clinicians to administer more active treatments in these patients.

The prediction value of the pulmonary function test could not be evaluated in this study because 14 patients in early death group did not accept the lung function test for early death or intolerability. In terms of albumin levels, it is widely accepted that patients with hypoalbuminemia do not recover easily; however, there is currently no data to directly verify the relationship between albumin level and prognosis of patients with MDA5+DM. In 2020, a prediction model using CRP and Krebs Von den Lungen-6 (KL-6) combined with the anti-MDA5 antibody was shown to be useful for predicting prognosis of patients with DM-ILD (27). As for ferritin, many studies have shown that serum ferritin levels were not only related to the severity of interstitial pneumonia in patients (28) but also predicted the risk of death (29). Recently, a FLAIR model was developed that combined five clinical indices, which included ferritin, lactate dehydrogenase, MDA5 antibody, HRCT Imagine semi-quantitative score, and rapidly-progressive ILD, to predict amyopathic dermatomyositis survival time (30). This FLAIR model was a multivariable model with rigorously established cutoff values that can be applied by clinicians in a uniform way. The 1-year survival in the discovery and validation cohorts were 34.3% and 15.0% for the high-risk group. This will provide a guidepost for making decisions around how aggressively to immunosuppress (31). Our study showed four factors including age of onset, ferritin, value of ELVAR and oxygen supplementation >4 L/min predicted significantly value for poor prognosis in MDA5+DM patients, which was consistent with FLAIR model to some extent. Above all, these findings highlight the value and importance of quantitative lung involvement of ILD. Our research based on computer-based image analysis technology that attempt to directly quantify lung interstitial lesions, which was simpler and more quantitative than FLAIR’s multi-index model, and had a certain degree of innovation.

As an exploratory study that combined computer image analysis and prognosis of MDA5+DM, several limitations may be noticed. First, this was a single-center study, and more
data from multi-centers are needed to confirm the efficiency of ELVAR values. Second, the role of ELVAR needs to be verified among different diseases’ associated ILD. Third, identification will be needed regarding whether computer-aided analysis of lung HRCT based on Siemens system can be applied to GE or Samsung system.

**CONCLUSION**

An index named by ELVAR basing on lung segmentation and lung interstitial enhancement was successfully established. The study aimed to assess the role of ELVAR value in predicting early death from interstitial pneumonia secondary to MDA5<sup>+</sup>DM. A retrospective analysis of 46 healthy controls and 55 patients with MDA5<sup>+</sup>DM from a single center found that the ELVAR value of healthy controls was stable at around 0.938, whereas MDA5<sup>+</sup>DM patients had lower values. Results showed that early mortality within 3 months of onset in patients with ELVAR values lower than 0.835 was significantly high as 54.2%. This novel index may be valuable for clinicians to efficiently identify severe patients and administer more active treatments.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**REFERENCES**

1. András C, Bodoki L, Nagy-Vincze M, Griger Z, Csüki E, Dankó K. Retrospective analysis of cancer-associated myositis patients over the past 3 decades in a hungarian myositis cohort. Pathol Oncol Res. (2020) 26:1749–55. doi: 10.1007/s11253-019-00756-4
2. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, medicare supplemental insured, and medicaid enrolled populations: an administrative claims analysis. BMC Musculoskelet Disord. (2012) 13:103. doi: 10.1186/1471-2474-13-103
3. Dias Junior AG, Sampaio NG, Rehwinkel J. A balancing act: MDA5 in anti-viral immunity and autoinflammation. Trends Microbiol. (2019) 27:75–85. doi: 10.1016/j.timi.2018.08.007
4. Baechler EC, Bilgic H, Reed AM. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. (2011)13:249. doi: 10.1186/ar3531
5. Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford). (2019) 58:786–91. doi: 10.1093/rheumatology/key386
6. Labrador-Horrillo M, Martinez MA, Selva-O’Callaghan A, Trallero-Araguás E, Balada E, Vilardeíl-Tarres M, et al. Anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis. J Immunol Res. (2014) 2014:290797. doi: 10.1155/2014/290797
7. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken). (2016) 68:689–94. doi: 10.1002/acr.22728
8. Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. (2012) 32:3909–15. doi: 10.1007/s00296-011-2332-y
9. Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri SY, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). (2012) 51:1278–84. doi: 10.1093/rheumatology/ker318
10. Yoshiida N, Okamoto M, Kaeda S, Fujimoto K, Ebata T, Tajiri M, et al. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respir Investig. (2017) 55:24–32. doi: 10.1016/j.resinv.2016.08.007
11. Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken). (2013) 65:1316–24. doi: 10.1002/acr.21985
12. Kim HG, Tashkin DP, Clements PJ, Li G, Brown MS, Elashoff R, et al. A computer-aided diagnosis system for quantitative scoring of extent of lung fibrosis in scleroderma patients. Clin Exp Rheumatol. (2010) 28(5 Suppl 62):S26–35.
13. Goldin JG, Kim GHI, Tseng CH, Volkmann E, Forst D, Clements P, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. Ann Am Thorac Soc. (2018) 15:1286–95. doi: 10.1513/AnnalsATS.201802-079OC
14. Bartholmai BJ, Raghunath S, Karwoski RA, Moua T, Rajagopalan S, Maldonado F, et al. Quantitative computed tomography imaging of interstitial lung diseases. J Thorac Imaging. (2013) 28:298–307. doi: 10.1097/RTI.0b013e3182a21969
15. Hosein KS, Sergiacomi G, Zompatori M, Mura M. The CALIPER-Revised version of the composite physiologic index is a better predictor

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Ethics Committee of Second Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**AUTHOR CONTRIBUTIONS**

CW, XM, and FeL designed the research. CW, LG, and FaL developed the computer-aided image analysis technology. XM and HL evaluated the ILD diagnosis of MDA5<sup>+</sup>DM. CW, JD, and FeL were responsible for the statistical analysis. CW and FeL wrote the paper. All authors contributed to the article and approved the submitted version.

**FUNDING**

National foundation of HUNAN province (2021J)30934); Educational Fund of Hunan Provincial Finance Department (2021-22-2050205); 225 Talent Project of Hunan Provincial Health Committee (2019-196); and Project of Changsha Science and Technology Bureau (kq1901119).
of survival in IPF than the original version. Lung. (2020) 198:169–72. doi: 10.1007/s00408-019-00295-4
16. Bell RD, Rudmann C, Wood RW, Schwarz EM, Rahimi H. Longitudinal micro-CT as an outcome measure of interstitial lung disease in TNF-transgenic mice. PLoS ONE. (2018) 13:e0190678. doi:10.1371/journal.pone.0190678
17. Mammen AL, Allenbach Y, Stenzel W, Benveniste O. ENMC 239th workshop study group. 239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 december 2018. Neuro muscular Disord. (2020) 30:70–92. doi: 10.1016/j.nmd.2019.10.005
18. Wu W, Guo L, Fu Y, Wang K, Zhang D, Xu W, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol. (2021) 60:293–304. doi: 10.1007/s12016-020-08822-5
19. Gerard SE, Herrmann J, Kazcza DW, Musch G, Fernandez-Bustamante A, Reinhardt JM. Multi-resolution convolutional neural networks for fully automated segmentation of acutely injured lungs in multiple species. Med Image Anal. (2020) 60:101592, doi: 10.1016/j.media.2019.10.1592
20. Hu S, Hoffman EA, Reinhardt JM. Automatic lung segmentation for accurate quantification of volumetric X-ray CT images. IEEE Trans Med Imaging. (2001) 20:490–8. doi: 10.1109/42.929615
21. Qi S, van Triest HJ, Yue Y, Xu M, Kang Y. Automatic pulmonary fissure detection and lobe segmentation in CT chest images. Biomed Eng Online. (2014) 13:59. doi: 10.1186/1475-925X-13-59
22. Ross JC, Kindlmann GL, Okajima Y, Hatabu H, Diaz AA, Silverman EK, et al. Pulmonary lobe segmentation based on ridge surface sampling and shape model fitting. Med Phys. (2013) 40:121903. doi: 10.1118/1.4828782
23. Phellan R, Falckó AX, Udupa JK. Medical image segmentation via atlases and fuzzy object models: improving efficacy through optimum object search and fewer models. Med Phys. (2016) 43:401. doi: 10.1118/1.4938577
24. Xu W, Wu W, Zhang D, Chen Z, Tao X, Zhao J, et al. A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis. Sci Rep. (2021) 11:17070. doi: 10.1038/s41598-021-96292-w
25. Guo LC, Wang CJ, Li FZ, He HJ, Li F. Binary surface smoothing for abnormal lung segmentation. Comput Graph. (2020) 89:68–76. doi: 10.1016/j.cag.2020.05.011
26. Neji H, Attia M, Affes M, Baccouche I, Ben Miled-M’rad K, Hantous-Znadd S. Interstitial lung diseases: imaging contribution to diagnosis and elementary radiological lesions. Semin Diagn Pathol. (2018) 35:297–303. doi:10.1053/j.semdp.2018.07.001
27. Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, et al. A multicenter retrospective cohort of Japanese patients with myositis-associated ILD (JAMI) investigators. risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease. Arthritis Rheumatol. (2020) 73:677–86. doi: 10.1002/art.41566
28. Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, et al. Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol. (2018) 28:133–140. doi: 10.1080/14397595.2017.1318468
29. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford). (2010) 49:1713–9. doi: 10.1093/rheumatology/keq149
30. Li X, Zou J, Guo Q, Chen S, Lu L, Wang R, et al. Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest. (2020) 158:1535–45. doi: 10.1016/j.chest.2020.04.057
31. Baker MC, Chung L, Fiorentino DF. A mortality risk score model for clinically amyopathic dermatomyositis-associated interstitial lung disease: will it have the necessary “FLAIR” to improve clinical outcomes? Chest. (2020) 158:1307–9. doi: 10.1016/j.chest.2020.06.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Du, Mei, Guo, Li, Luo and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.